Safety and Effectiveness of Switching to Abacavir/Lamivudine Plus Rilpivirine for Maintenance Therapy in Virologically Suppressed HIV-1 Individuals in Singapore (SEALS)

Overview

Journal AIDS Res Ther

Publisher Biomed Central

Specialty Infectious Diseases

Date 2021 Nov 2

PMID 34724931

Authors

Z C Lim

G S Hoo

J H Ang

C B Teng

L W Ang

C C Lee

Y S Leo

H L Law

O T Ng

C S Wong

Affiliations

Soon will be listed here.

Abstract

Background: The efficacy and tolerability of an antiretroviral regimen are important considerations for selection of HIV-1 infection maintenance therapy. Abacavir/lamivudine plus rilpivirine (ABC/3TC + RPV) has been shown in international studies to be effective and well-tolerated in virologically suppressed individuals. This study evaluated the effectiveness and safety of switching to ABC/3TC + RPV as maintenance therapy in virologically suppressed HIV-1 infected individuals in Singapore.

Methods: In this retrospective, single-centre study, we included individuals who were prescribed ABC/3TC + RPV, had HIV-1 viral load (VL) < 50 copies/ml immediately pre-switch, and had no documented history of resistance mutations or virologic failure to any of the components. The follow-up period was 48 ± 12 weeks. The primary outcome was the proportion of individuals who maintained virologic suppression of HIV-1 VL < 50 copies/ml at the end of follow-up period based on on-treatment analysis. The secondary outcomes were the resistance profiles associated with virologic failure, changes in immunologic and metabolic parameters, and the safety profile of ABC/3TC + RPV.

Results: A total of 222 individuals were included in the study. The primary outcome was achieved in 197 individuals [88.8%, 95% confidence interval: 83.7-92.4%]. There were 21 individuals (9.5%) who discontinued treatment for non-virologic reasons. The remaining 4 individuals experienced virologic failure, of whom, 3 of these individuals had developed emergent antiretroviral resistance and had HIV-1 VL > 500 copies/ml at the end of the 48 ± 12 weeks follow-up period. The remaining individual experienced sustained low level viremia and subsequently achieved viral suppression without undergoing resistance testing. A total of 49 adverse events were observed in 31 out of 222 individuals (14.0%), which led to 13 individuals discontinuing therapy. Neuropsychiatric adverse events were most commonly observed (53.1%). A statistically significant increase in CD4 was observed (p < 0.01), with a median absolute change of 31 cells/uL (interquartile range: - 31.50 to 140.75). No significant changes in lipid profiles were detected.

Conclusion: ABC/3TC + RPV is a safe and effective switch option for maintenance therapy in virologically suppressed HIV-1 individuals with in Singapore.

References

Alvarez A, Orden S, Andujar I, Collado-Diaz V, Nunez-Delgado S, Galindo M . Cardiovascular toxicity of abacavir: a clinical controversy in need of a pharmacological explanation. AIDS. 2017; 31(13):1781-1795. DOI: 10.1097/QAD.0000000000001547. View

Troya J, Ryan P, Ribera E, Podzamczer D, Hontanon V, Terron J . Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study. PLoS One. 2016; 11(10):e0164455. PMC: 5058546. DOI: 10.1371/journal.pone.0164455. View

Cohen C, Andrade-Villanueva J, Clotet B, Fourie J, Johnson M, Ruxrungtham K . Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. Lancet. 2011; 378(9787):229-37. DOI: 10.1016/S0140-6736(11)60983-5. View

Mendes de Cordova C, de Cordova M . A new accurate, simple formula for LDL-cholesterol estimation based on directly measured blood lipids from a large cohort. Ann Clin Biochem. 2012; 50(Pt 1):13-9. DOI: 10.1258/acb.2012.011259. View

Gazaignes S, Resche-Rigon M, Gatey C, Yang C, Denis B, Fonsart J . Efficacy and safety of a switch to rilpivirine-based regimens in treatment-experienced HIV-1-infected patients: a cohort study. Antivir Ther. 2015; 21(4):329-36. DOI: 10.3851/IMP3010. View

Galizzi N, Galli L, Poli A, Gianotti N, Carini E, Bigoloni A . Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load. PLoS One. 2018; 13(2):e0191300. PMC: 5815573. DOI: 10.1371/journal.pone.0191300. View

Newcombe R . Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med. 1998; 17(8):857-72. DOI: 10.1002/(sici)1097-0258(19980430)17:8<857::aid-sim777>3.0.co;2-e. View

Karve S, Cleves M, Helm M, Hudson T, West D, Martin B . Prospective validation of eight different adherence measures for use with administrative claims data among patients with schizophrenia. Value Health. 2009; 12(6):989-95. DOI: 10.1111/j.1524-4733.2009.00543.x. View

Colombo G, Colangeli V, Di Biagio A, Di Matteo S, Viscoli C, Viale P . Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. Clinicoecon Outcomes Res. 2011; 3:197-205. PMC: 3234156. DOI: 10.2147/CEOR.S24130. View

10.

Bezabhe W, Chalmers L, Bereznicki L, Peterson G . Adherence to Antiretroviral Therapy and Virologic Failure: A Meta-Analysis. Medicine (Baltimore). 2016; 95(15):e3361. PMC: 4839839. DOI: 10.1097/MD.0000000000003361. View

11.

Andrassy K . Comments on 'KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease'. Kidney Int. 2013; 84(3):622-3. DOI: 10.1038/ki.2013.243. View

12.

Swartz J, Vandekerckhove L, Ammerlaan H, de Vries A, Begovac J, Bierman W . Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in Europe. J Antimicrob Chemother. 2015; 70(6):1850-7. DOI: 10.1093/jac/dkv033. View

13.

Ho S, Wong J, Ng O, Lee C, Leo Y, Boon Lye D . Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naïve HIV-1 infected adults. AIDS Res Ther. 2020; 17(1):23. PMC: 7243331. DOI: 10.1186/s12981-020-00272-5. View

14.

Molina J, Clumeck N, Orkin C, Rimsky L, Vanveggel S, Stevens M . Week 96 analysis of rilpivirine or efavirenz in HIV-1-infected patients with baseline viral load ≤ 100 000 copies/mL in the pooled ECHO and THRIVE phase 3, randomized, double-blind trials. HIV Med. 2013; 15(1):57-62. DOI: 10.1111/hiv.12071. View

15.

Molina J, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M . Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet. 2011; 378(9787):238-46. DOI: 10.1016/S0140-6736(11)60936-7. View

16.

Dorjee K, Choden T, Baxi S, Steinmaus C, Reingold A . Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: A systematic review and meta-analyses of results from 17 epidemiologic studies. Int J Antimicrob Agents. 2018; 52(5):541-553. PMC: 7791605. DOI: 10.1016/j.ijantimicag.2018.07.010. View

17.

Palacios R, Perez-Hernandez I, Martinez M, Mayorga M, Gonzalez-Domenech C, Omar M . Efficacy and safety of switching to abacavir/lamivudine (ABC/3TC) plus rilpivirine (RPV) in virologically suppressed HIV-infected patients on HAART. Eur J Clin Microbiol Infect Dis. 2016; 35(5):815-9. DOI: 10.1007/s10096-016-2602-3. View

18.

Curran A, Rojas J, Cabello A, Troya J, Imaz A, Domingo P . Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients. J Antimicrob Chemother. 2016; 71(12):3510-3514. DOI: 10.1093/jac/dkw347. View

19.

Casado J, Banon S . Recent advances in rilpivirine: new data and promising treatment option. AIDS Rev. 2014; 16(3):172-81. View

20.

Giannini E, Testa R, Savarino V . Liver enzyme alteration: a guide for clinicians. CMAJ. 2005; 172(3):367-79. PMC: 545762. DOI: 10.1503/cmaj.1040752. View